# Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

> **NCT01735630** · PHASE2 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 350 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ELND005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01735630
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01735630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01735630, "Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01735630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*